Background: Inhibitors of apoptosis (IAPs) are a family of cell death inhibitors found in viruses and metazoans. All IAPs have at least one baculovirus IAP repeat (BIR) motif that is essential for their anti-apoptotic activity. IAPs physically interact with a variety of pro-apoptotic proteins and inhibit apoptosis induced by diverse stimuli. This allows them to function as sensors and inhibitors of death signals that emanate from a variety of pathways.
Background
Apoptosis is a cell suicide mechanism with a major role in development and homeostasis in vertebrates and invertebrates [1] . Dysregulation of apoptosis leading to early cell death or the absence of normal cell death contributes to a number of disease states including neurodegenerative disorders and cancer [2] . It is becoming evident that inhibition of apoptosis enhances the survival of cancer cells and facilitates their escape from immune surveillance and cytotoxic therapies. Among the principal molecules contributing to this phenomenon are inhibitors of apoptosis (IAPs) [3] .
IAPs were originally identified in baculoviruses by their ability to substitute functionally for the powerful antiapoptotic P35 viral gene product [4] [5] [6] . Subsequently, homologs of IAPs have been discovered in both invertebrates and vertebrates [3, [7] [8] [9] [10] [11] [12] [13] [14] [15] . Members of the IAP family are characterized by the presence of at least one, and usually two or three, tandem baculovirus IAP repeat (BIR) motifs. In addition, most also possess a carboxy-terminal RING finger motif [16] . IAPs interact with multiple cellular partners and inhibit apoptosis induced by a variety of stimuli [3] . For example, baculovirus Op-IAP and Cp-IAP and Drosophila D-IAP1 and D-IAP2 bind and inhibit apoptosis induced by Reaper, Hid, and Grim, which are the principal developmental inducers of apoptosis in the fly [17, 18] .
The anti-apoptotic activity of some IAPs has been attributed to their ability to inhibit caspases [19] [20] [21] , which are cysteine-dependent aspartate-specific proteases that comprise the effector arm of the cell death pathway [22] . For instance, X-IAP, C-IAP1, and C-IAP2 inhibit active caspases 3 and 7 and the Apaf-1-cytochrome-c-mediated activation of caspase-9 [23] [24] [25] . Some IAPs are not involved in cell death, however, but are instead involved in regulating the cell cycle. These are exemplified by human survivin, a RING-less IAP which is expressed in the G2-M phase of the cell cycle and localizes to mitotic spindle microtubules where it influences mitotic progression [26, 27] . Survivin has a striking pattern of expression as its transcript is found in many cancers and in fetal, but not adult, differentiated tissues [14, 28] . Here we describe a new human IAP, ML-IAP, whose expression, like that of survivin, is markedly increased in many transformed cells and embryonic tissues. Notably, the majority of melanoma cell lines overexpress ML-IAP. As we show ML-IAP to be a potent inhibitor of apoptosis induced by engagement of death receptors and exposure to tumoricidal drugs, its overexpression may have an important role in the evolution of this and other malignancies.
Results

ML-IAP is a new member of the IAP family
Search of the LifeSeq database (Incyte Pharmaceuticals) for sequences homologous to IAP family members identified a previously unknown human sequence related to the BIR domain. Sequence analysis revealed two almost identical cDNAs that differed only by the presence of an extra 54 nucleotides. Both cDNAs encoded predicted proteins, of 280 and 298 amino acids respectively, containing a single BIR and RING finger motif characteristic of the IAP family ( Figure 1a ). The 18 amino acids that differentiate these two proteins are located between the BIR and the RING finger motifs (Figure 1a) . We used the shorter form in the majority of experiments as no functional difference was discernible between these two forms (see below). Protein sequence alignments demonstrated significant homology of the ML-IAP BIR and RING finger motifs to corresponding motifs present in human X-IAP, C-IAP1 and C-IAP2 (Figure 1b,c) . The BIR motif of ML-IAP appears to be most similar to the central (second) and carboxy-terminal (third) BIRs of X-IAP, C-IAP1 and C-IAP2 (Figure 1b ) and may represent a hybrid of these two BIR subgroups [29] .
Expression of ML-IAP transcript was assessed by northern blot analysis. It revealed two mRNA species of 1.5 and 2.2 kb in size that arise from probable use of alternative polyadenylation signals present in the 3′ untranslated region. The strongest signal was detected in melanoma cell lines but also in some lymphomas, fetal kidney, fetal liver, testis and thymus (Figure 1d ). Given the elevated expression in melanoma cell lines (Figures 1d,7) , we termed this new IAP family member ML-IAP for melanoma IAP. In keeping with a potential role in cancer, the genomic locus for ML-IAP mapped to a region (chromosome 20q13) that is frequently amplified in melanomas and colon, lung, and colorectal malignancies [30] [31] [32] .
As survivin, another cancer-associated IAP, localizes to mitotic spindles, we determined the subcellular localization of ML-IAP. As evident from Figure 1e , ML-IAP and its RING finger localized predominantly to the cytoplasm of MCF7 breast cancer cells and not to mitotic The open reading frame for ML-IAP reveals the presence of a single BIR domain and the RING finger (both underlined). The boxed area represents the difference between isolated ML-IAP cDNAs. Amino acid sequence alignments of (b) BIR and (c) RING finger domains from human IAPs. (d) Tissue distribution of the ML-IAP mRNA. Human adult and fetal multiple-tissue and cancer cell line northern blots (Clontech) were probed with an internal fragment of ML-IAP cDNA according to the manufacturer's instructions. (e) Subcellular localization of ML-IAP and ML-IAP RING. MCF7 cells stably transfected with ML-IAP, ML-IAP RING or vector were stained with the ML-IAP antiserum and anti-α-and β-tubulin monoclonal antibody followed by Cy5-conjugated anti-rabbit antibody and FITC-conjugated anti-mouse antibody, respectively. Staining was observed by confocal microscopy. (a) (Figure 1e ). Thus, in contrast to survivin, ML-IAP does not localize to mitotic spindles.
Apoptosis induced by death receptors and chemotherapeutic agents is inhibited by ML-IAP
To determine whether ML-IAP can inhibit apoptosis induced by death receptors, we expressed Fas, TNFR1, DR4 and DR5 in MCF7 cells with either vector, or ML-IAP or known inhibitors of apoptosis. Expression of ML-IAP efficiently blocked apoptosis induced by engagement of Fas, TNFR1, DR4 and DR5 (Figure 2a) . Inhibition of death receptor-induced apoptosis by ML-IAP was comparable in potency to that obtained with previously characterized inhibitors including p35, X-IAP and C-IAP1 ( Figure 2a ).
Next we determined if ML-IAP could inhibit apoptosis induced by chemotherapeutic agents. Adriamycin was chosen as it is readily water soluble, eliminating the problem of vehicle toxicity, and used widely in clinical oncology. Adriamycin was a powerful inducer of cell death in MCF7 cells as evidenced by typical apoptotic morphological alterations including rounding of cells, membrane blebbing and eventual detachment from the dish (data not shown). ML-IAP was as efficient as the positive control X-IAP in blocking adriamycin-induced apoptosis ( Figure 2b ). Additionally, we tested the potent apoptosisinducing agent 4-tertiary butylphenol (4-TBP) [33] and found that ML-IAP effectively blocked 4-TBP-induced cell death ( Figure 2b ). These results indicate that ML-IAP is a potent inhibitor of death-receptor-and chemotherapeuticagent-induced apoptosis.
As some IAPs function as caspase inhibitors [23] [24] [25] , we investigated whether ML-IAP shares similar caspaseinhibitory activity. Among the several caspases tested, ML-IAP was most effective in inhibiting caspase-3, a downstream effector caspase ( Figure 3a ). The degree of inhibition of caspase-3 activity was comparable to that by C-IAP1 (Figure 3a) . In contrast, ML-IAP did not effectively block the activity of caspase-7, a caspase that is potently inhibited by C-IAP1 (Figure 3a) . This difference in ability to block caspase-7 activity correlated with the results of binding studies where caspase-7 was found to bind C-IAP1, but not ML-IAP (Figure 3b ). Like the other IAPs, including X-IAP, C-IAP1 and C-IAP2, ML-IAP did not inhibit caspases 1, 2, 6 or 8 (data not shown). We also analyzed the effect of ML-IAP on the activation of caspases by the mitochondrial/cytochrome c pathway that results in Apaf-1-mediated activation of caspase-9. ML-IAP inhibited cytochrome-c-mediated activity of caspase-9 in cytosolic extracts, though not as strongly as C-IAP1 ( Figure 3c , upper panel). In addition, immunoprecipitation of ML-IAP and C-IAP1 co-precipitated caspase-9, confirming physical interaction between the IAPs and the inhibited caspases (Figure 3c, lower panel) . Thus, ML-IAP can inhibit caspase-3 and caspase-9.
The BIR domain of ML-IAP is responsible for its antiapoptotic activity
To identify the region of ML-IAP responsible for inhibiton of apoptosis, we separately expressed the BIR and the RING finger domains, with or without adjoining spacer sequences (Figure 4a,b) . Analysis of the ability of these ML-IAP constructs to inhibit Fas-and TNFR1-induced apoptosis revealed that an intact BIR domain was necessary Following transfection, cells were stained with X-gal and apoptosis assessed as described previously [41] . Percentage apoptosis represents the mean value from three independent experiments. A three-dimensional model of the BIR domain of ML-IAP was built on the basis of sequence similarity by homology modeling, using the NMR structure coordinates of BIR2 of X-IAP and BIR3 of C-IAP1 as templates [29, 34] (Figure 5 ). Threading analysis indicated that the ML-IAP BIR closely resembled X-IAP BIR2, possessing four α helices and a three-stranded antiparallel β sheet, as well as corresponding residues that form the hydrophobic core ( Figures 5,6b ). The ML-IAP BIR has a carboxy-terminal extension that shares strong sequence similarity with the carboxy-terminal BIR (BIR3) from C-IAP1 and so this was used as a template for modeling the corresponding segment in the ML-IAP BIR domain ( Figures 5,6b ). Amino acid residues C124, C127, H144 and C151 are predicted to coordinate Ribbon diagrams of the structures for the BIR2 domain of X-IAP, BIR3 of C-IAP1 and the modeled structure for BIR of ML-IAP. α Helices are depicted by cylinders and β sheets by arrows. The side chains of the residues that chelate zinc (displayed as a sphere) are indicated.
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zinc and stabilize the overall fold [34] ( Figure 5 ). The surface of the ML-IAP BIR is characterized by a number of charged residues, the majority of which are well conserved within the IAP family (Figure 6a,b) .
To assess the functional importance of surface amino acid residues, we mutated several conserved and some nonconserved residues to alanine (Figure 6c,d) . As a control, we mutated a cysteine that is one of the C 2 HC zinc-coordinating residues to produce a non-functional BIR domain. Of the 1 double and 12 single mutants tested, 3 single mutants showed a substantial decrease in their ability to inhibit Fas-and TNFR1-induced apoptosis (Figure 6c,d) . Not surprisingly, the most profound loss in inhibitory activity was observed by mutating the structurally important zinc-coordinating cysteine 124 (Figure 6c ). In addition to this residue, mutating aspartates 120 and 138 also abolished the ability of ML-IAP to inhibit death-receptorinduced apoptosis (Figure 6c ). To test whether caspase inhibition contributed to the anti-apoptotic mechanism of ML-IAP, we determined whether apoptosis-inactivating mutations also abolished the ability to inhibit caspase activity. Mutations such as the double glutamate 87 and 88 alterations to alanine, which displayed anti-apoptotic activity comparable to the wild-type molecule, also inhibited caspase activity, whereas the aspartate 120 mutant, which lost anti-apoptotic activity, showed no caspaseinhibitory activity (Figure 6e ). Therefore, this preliminary analysis suggests that the anti-apoptotic activity of ML-IAP correlates with its ability to act as a caspase inhibitor.
ML-IAP is strongly upregulated in melanomas
Given the abundance of ML-IAP mRNA in G361 melanoma cells (Figure 1d) , we extended the analysis of transcript levels to additional melanoma cell lines. All cell lines examined contained raised amounts of ML-IAP message (Figure 7a ). This was in sharp contrast to normal human melanocytes (NHEM) where the message was undetectable (Figure 7a ). Examination of endogenous ML-IAP protein levels in two melanoma cell lines (888, 624) and in melanocytes (NHEM) correlated with expression of the transcript (Figure 7b ).
As the raised levels of ML-IAP could contribute to the resistance of melanomas to pro-apoptotic chemotherapeutic agents, we investigated the sensitivity of melanoma cell lines and primary melanocytes to the skin-damaging agent 4-TBP. Treatment with 4-TBP rapidly induced -IAP  E87,88A  L91A  L99A  E102A  E106A  D120A  C124A  R136A  D138A  K146A  R156A  R160A  D161A   + Fas   Vector  ML-IAP  E87,88A  L91A  L99A  E102A  E106A  D120A  C124A  R136A  D138A  K146A  R156A  R160A  D161A   + TNFR1 ML 
Discussion
Viability assays of ML-IAP showed it to be a powerful inhibitor of apoptosis induced by death receptors and chemotherapeutic agents. As both death receptor and intrinsic cell death pathways converge at the point of caspase activation, we anticipated that ML-IAP might block caspase activity. Caspase-3 was inhibited by ML-IAP but caspase-7, a related downstream effector caspase, was only marginally inhibited under the test conditions. ML-IAP did, however, inhibit caspase-9, the initiating caspase in the mitochondrial pathway responsible for drug-induced death. As we did not test all known caspases, it is possible that ML-IAP may inhibit additional members of this death protease family. IAPs can modulate cell survival by mechanisms other than caspase inhibition. For instance, C-IAP1 and C-IAP2 physically interact with TRAF-1 and TRAF-2 within the TNF receptor complex and may, by this mechanism, confer resistance to TNF-induced apoptosis [7, 35] . Our initial studies suggest that ML-IAP does not bind TRAFs nor is its expression modulated by TNFα (data not shown). Regardless, ML-IAP may interact with other yet to be defined non-caspase cellular factors to inhibit cell death.
IAPs are characterized by the presence of BIR and RING finger motifs. The BIR region of IAPs is responsible for anti-apoptotic activity and most protein-protein interactions [16, 36, 37] . Although ML-IAP is unique in possessing a single BIR and RING finger, its BIR domain is structurally most related to the BIR2 of X-IAP. Mutations in residues conserved in the BIR of ML-IAP and BIR2 of X-IAP (E87,88A and D120A) have the same influence on anti-apoptotic function [34] , implying similar overall structure of BIR domains. This is also suggested by sequence comparison and three-dimensional modeling studies, which revealed strong structural similarity between the various BIR domains, especially the carboxy-terminal portions of ML-IAP BIR and C-IAP1 BIR3 [29] . This region has been implicated as essential for inhibition of apoptosis and for the binding by baculovirus Op-IAP to physiological inducers of apoptosis such as Drosophila Hid, Reaper and Grim [36] . These observations suggest that the ML-IAP BIR may interact with mammalian counterparts of the Drosophila cell death proteins. In addition to variations within the BIR, ML-IAP lacks a sequence upstream of the BIR2 domain which is important for caspase inhibition by BIR2 of X-IAP [34] . This difference between X-IAP and ML-IAP could in part explain the difference in the caspase-inhibition profile of these two IAPs.
The existence of multiple IAPs and their differing spatiotemporal expression patterns suggests an organ-specific role in promoting cell survival during development and tissue homeostasis. While X-IAP, C-IAP1 and C-IAP2 are relatively ubiquitously expressed, NAIP has a more restricted expression pattern and survivin is expressed only in fetal and tumor tissues [3] . ML-IAP has a rather selective expression pattern, as it is predominantly detected in melanomas and a few other tissues (Figures 1,7) . The ML-IAP is highly expressed in melanomas.
(a) Analysis of ML-IAP mRNA levels in melanoma cell lines by RT-PCR. The amount of RNA was normalized using primers specific for glyceraldehyde-3-phosphate dehydrogenase (G3PDH). The origin of the RNA samples has been described [42, 43] . NHEM  501  537  553  624  677  697  888A  888B  928  1011  1088A  1088B  1143  1182  1241  1241  1278  1280  1286  1287  1300  1308  1317  1335  1338  1359  1376  1379  1383  1402 only other IAP with well-documented expression in melanomas is survivin [38] . Like survivin, ML-IAP can be detected in the majority of melanoma cell lines tested but not in normal melanocytes. Melanoma cell lines with high levels of ML-IAP are relatively more resistant to apoptotic stimuli than are normal primary melanocytes. Thus, ML-IAP might be a critical cellular factor whose increased expression confers resistance to apoptotic stimuli, thereby contributing to the pathogenesis and progression of malignant melanomas.
Materials and methods
Isolation of ML-IAP cDNA
We searched the LifeSeq database (Incyte Pharmaceuticals) for sequences homologous to the BIR region of IAP family members. A novel sequence related to the BIR of IAPs was identified and several clones containing full-length or partial sequences were obtained from Incyte Pharmaceuticals.
Northern blot analysis and chromosomal localization
Adult and fetal human multiple-tissue and cancer cell line northern blots (Clontech) were hybridized according to the manufacturer's instructions with the 32 P-labeled probe comprising nucleotides 241-861 of the ML-IAP open reading frame. Chromosomal localization of ML-IAP was determined by radiation-hybrid analysis.
Three-dimensional modeling and sequence analysis
The HOMOLOGY/MODELLER module from the InsightII package (version 98.0; MSI, San Diego, California) was used for molecular construction and display. Threading analysis was carried out using the ProCeryon software (ProCeryon Biosciences 1999 -2000 . Amino acid sequence alignments were performed using ClustalW with gap distance of 8, open gap penalty of 2.1, extend gap penalty of 0.2 and the blosum similarity matrix.
Expression vectors, mutagenesis and antibodies
Plasmids expressing β-galactosidase, p35, Myc-C-IAP1, FLAG-Fas, FLAG-TNFR1, FLAG-DR4, and FLAG-DR5 have been previously described [39] [40] [41] . Myc-ML-IAP and Myc-XIAP were generated by PCR using custom-made primers encoding an amino-terminal Myc tag. Amplified products were cloned into the mammalian expression vector pcDNA3.1. Deletion mutants were generated by PCR with an amino-terminal Myc tag and then subcloned into pcDNA3.1. Site-specific mutants were generated using Myc-tagged ML-IAP in the pcDNA3.1 background as a template using the Quick Change site-directed mutagenesis kit (Stratagene). C-IAP1, ML-IAP and indicated ML-IAP mutants were subcloned into pGEX-6P-1 vector (Pharmacia) for expression of IAPs tagged with glutathione-S-transferase (GST). Antiserum specific for ML-IAP was raised against a bacterially expressed and purified amino-terminally His-tagged version of the molecule (Zymed).
Cell cultures, western blot analysis and immunoprecipitation
Human 293T embryonic kidney cells and MCF7 human breast carcinoma cells were cultured as previously described [40] . The melanoma cell lines 624 and 888 were generated from metastatic lesions and maintained as described [42, 43] . Human neonatal epidermal melanocytes, NHEM, were grown according to the supplier's instructions (Clonetics). Constructs expressing deletions and mutations of ML-IAP were transiently transfected in 293T cells using GenePorter reagent (Gene Therapy Systems) and 24 h later lysed in NP-40 lysis buffer [17, 18] . For western analysis, lysates were resolved by SDS-PAGE, transferred to Immobilon P membrane (Millipore) and immunoblotted as described [40] . For immunoprecipitation, 10 7 cells were lysed in NP-40 lysis buffer and precleared with nonspecific antibody and protein G agarose (Sigma). Lysates were then incubated with ML-IAP antiserum or preimmmune serum and the resulting immunocomplexes precipitated with protein G-agarose. Following extensive washing, the beads were boiled in sample buffer and the released material subjected to western blot analysis using ML-IAP antiserum essentially as described previously.
Immunofluorescence microscopy and ML-IAP stable cell lines
DNAs encoding ML-IAP and ML-IAP RING were cloned into the pCEP4 vector (Invitrogen) and stable clones were made in MCF7 cells using standard molecular biology techniques. MCF7 cells stably transfected with ML-IAP, ML-IAP RING or vector were treated with 10 µM taxol (Sigma), fixed in methanol and stained with the ML-IAP antiserum or anti-α and -β-tubulin monoclonal antibody (Sigma). Immunodetection of ML-IAP and tubulin, respectively, was carried out with Cy5-conjugated anti-rabbit antibody and FITC-conjugated anti-mouse antibody (Jackson Immunoresearch). Cells were examined and photographed using confocal microscopy (Leica SP).
Protein purification and caspase inhibition and binding assays
Purified recombinant caspases and recombinant GST-IAPs were expressed and isolated as previously described [44, 45] . Cytosolic extracts of HEK293 cells were also prepared as previously described [23, 46] . The IAPs were tested for their ability to inhibit purified recombinant caspases by adding a range of IAP concentrations to the caspases of interest in IAP buffer (10 mM Pipes, 100 mM NaCl, 0.1% Chaps, 10% sucrose, 20 mM β-mercaptoethanol pH 7.2). The mixture was incubated at 37°C for 20 min before addition of Z-DEVD-AFC (Enzyme System Products) to a final concentration of 100 µM. The hydrolysis of the substrate was followed as the increase in fluorescence at 500 nm upon excitation at 405 nm. The activity was determined as the initial rate of hydrolysis. For in vitro pull-down assay, 1.5 µM of purified recombinant caspase-7 was mixed with 0.6 µM of the GST-IAP of interest in IAP buffer and incubated at 37°C for 30 min. After incubation, glutathione-sepharose (Pharmacia) beads were added to the mixture for 1 h at 4°C followed by washing. The proteins bound to the beads were resolved by SDS-PAGE and western blot analysis was performed using mouse anti-caspase-7 (Pharmingen). The ability of the IAPs to inhibit the activation of cytosolic extracts by cytochrome c/dATP was tested in an online assay. Briefly, IAPs were added to 50 µl cytosolic extract, containing 400 µM Ac-DEVD-pNA (Bachem), to a final concentration of 350 nM. The activation was then initiated by addition of cytochrome c and dATP to a final concentration of 10 µM and 1 mM, respectively. The activation reaction was followed online as the increase in absorbance at 405 nm over time using a Molecular Devices SpectraMax 340 microplate reader at 37°C. The amount of active caspase-3 at 600 sec was determined as the tangent to the activation curve at this time point.
Apoptosis assays
MCF7 cells were transiently transfected with 0.2 µg of the reporter plasmid pCMV-βgal plus 0.2 µg of plasmid encoding Fas, TNFR1, DR4 or DR5 and 1.6 µg of plasmid encoding vector, baculovirus P35 or indicated human IAPs. For adriamycin or 4-TBP treatment, MCF7 cells were transiently transfected with the reporter plasmid pCMV-βgal and control vector or indicated human IAPs. Four hours following transfection, adriamycin (doxorubicin, Sigma) or 4-TBP (Aldrich) was added to the media at the indicated concentrations. Apoptosis was assayed 16 h later as described [41] . Melanoma cell lines (888, 624) or melanocytes (NHEM cells) were treated for 5 h with the indicated amounts of 4-TBP and viability assessed by FACS analysis using staining with propidium iodide and annexin V (Clontech).
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